Aug. 1 at 12:26 AM
$MIST Between
$0.90-
$1.10 You are buying the company at or near its net cash value. Commercial failure or delays are largely priced in. The risk is low. Buying near or close to net cash (~
$1.00 -
$1.15) effectively means paying almost zero enterprise value for CARDAMYST and the AFib-RVR pipeline, giving you maximum downside protection against commercial delays.
Between
$1.15 –
$1.50 Enterprise Value (EV) sits around
$25M–
$60M. The market is pricing in modest CARDAMYST sales with significant skepticism. The risk is balanced.
Bottomline, the stock should bounce around here and
$1.50 until year end. If Optum Rx and CVS come on board before year end, the stock should trade up to
$2 or higher.
